Navigate with Confidence
The 340B Rebate Pilot
From upfront discounts to rebate-based pricing—QuicksortRx gives you the tools to stay compliant, plan, and act quickly in a shifting regulatory environment.
Request your personalized analysis for the proposed 340B Rebate Pilot Program.
A Pilot That Could Change Everything
On July 30 HRSA announced a proposed 340B Rebate Model Pilot Program. It shifts the benefit from upfront discounts to rebate-based reimbursements for over 400 NDCs tied to 10 IRA-selected drugs for 2026 and 15 selected drugs for 2027.
For covered entities, this means paying full WAC now—then waiting for rebate checks later. That delay could put significant cash flow pressures health systems. .png?width=157&height=159&name=Badge%20(3).png)
We built a tool to help our customers navigate the change.
340B Benefit Tool
Know the total 340B program impact—including estimated financial benefits and cash needs for all potential rebate models. See annual, monthly, and quarterly benefits, plus potential rebate exposure by your pharmacies and suppliers.
Pinpoint your hospital’s exposure under the proposed IRA NDC rebate pilot.
Know exactly how much cash you may need to float while waiting for rebate returns on the 400 IRA NDCs. Get ongoing insights into IRA medication spend, WAC changes, and rebate forecasts.
IRA NDC Report (NEW)
Pinpoint your hospital’s exposure under the new rebate model.
Know exactly how much cash you may need to float while waiting for rebate returns on the 400 IRA NDCs. Get ongoing insights into IRA medication spend, WAC changes, and rebate forecasts.
.png?width=2000&name=Mac%20Book%20(1).png)
IRA NDC Report (NEW)
Pinpoint your hospital’s exposure under the proposed IRA NDC rebate pilot.
Know exactly how much cash you may need to float while waiting for rebate returns on the 400 IRA NDCs. Get ongoing insights into IRA medication spend, WAC changes, and rebate forecasts.